Zobrazeno 1 - 10
of 133
pro vyhledávání: ''
Autor:
Flaminia Campo, Antonia La Malfa, Davide Renna, Emanuela Taraborelli, Maria Teresa Maccallini, Fulvia Pimpinelli, Vittoria Barberi, Martina Pontone, Paolo Carlini, Laura Conti, Aldo Morrone, Fabrizio Petrone, Virginia Ferraresi, Ludovica Gariazzo, Raul Pellini, Gianluigi Ferretti, Vincenzo Di Noia, Alessandro Monti, Diana Giannarelli, Domenico Bracco, Chiara Mandoj, Ornella Di Bella, Francesco Cognetti, Maria Di Santo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(24)
Purpose: We assessed the immunogenicity and safety of the BNT162b2 vaccine in a large cohort of patients with cancer (CP). Experimental Design: From March 1, 2021 to March 20, 2021, this prospective cohort study included 816 CP afferent to our instit
Autor:
Isabell Schulze, Zoe Quandt, Alexander Gusev, Melinda C. Aldrich, Andrew J. Plodkowski, Mohsen Abu-Akeel, Jia Luo, Taha Merghoub, Victoria Martucci, Jacklynn V. Egger, Donglei Hu, Hira Rizvi, Matthew A. Gubens, Scott Huntsman, Megan H. Murray, Christine M. Lovly, Matthew D. Hellmann, Elad Ziv, Min Li, Stefan Groha, Eduardo Cardenas
Publikováno v:
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 18
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 18
Purpose: Genetic differences in immunity may contribute to toxicity and outcomes with immune checkpoint inhibitor (CPI) therapy, but these relationships are poorly understood. We examined the genetics of thyroid immune-related adverse events (irAE).
Autor:
Michael J. LaRiviere, Elena Helman, Taylor A. Black, Wei-Ting Hwang, Rebecca J. Nagy, Theresa Christensen, Benjamin A. Silva, Katie Quinn, Charu Aggarwal, Austin L. Chien, Abigail T. Berman, Erica L. Carpenter, Joshua Bauml, Jeffrey C. Thompson, Corey J. Langer, Christine Ciunci, Kimberly C. Banks, Jeffrey S. Wasser, Stephanie S. Yee, Aditi P. Singh, Roger B. Cohen
Publikováno v:
Clin Cancer Res
Purpose: The role of plasma-based tumor mutation burden (pTMB) in predicting response to pembrolizumab-based first-line standard-of-care therapy for metastatic non–small cell lung cancer (mNSCLC) has not been explored. Experimental Design: A 500-ge
Autor:
Philippe Masson, Denis Moro-Sibilot, Isabelle Monnet, Anne-Claire Toffart, Bertrand Mennecier, Didier Debieuvre, E. Amour, Eric Pichon, Fabrice Barlesi, Olivier Molinier, Franck Morin, Patrick Aldo Renault, Anne Madroszyk-Flandin, Séverine Fraboulet, Isabelle Rouquette, Alexis B. Cortot, Pierre Jean Souquet, Virginie Westeel, Sandrine Hiret, Clarisse Audigier-Valette, Julien Mazieres, Benjamin Besse, Gérard Zalcman
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(13)
Purpose: The incidence of lung cancer has dramatically increased in women. Preclinical data have suggested that combining EGFR–tyrosine kinase inhibitor (TKI) with an antiestrogen may overcome resistance to EGFR-TKI. Patients and Methods: The IFCT-
Autor:
T. Jeroen N. Hiltermann, Diana C.J. Spierings, Sanne de Wit, Kiki C. Andree, Caroline van der Wauwer, Menno Tamminga, Harry J.M. Groen, Joost F. Swennenhuis, Wim Timens, Anke van den Berg, Peter M. Lansdorp, Leon W.M.M. Terstappen, Hilda van den Bos, Theo J. Klinkenberg
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(7)
Purpose: Tumor cells from patients with lung cancer are expelled from the primary tumor into the blood, but difficult to detect in the peripheral circulation. We studied the release of circulating tumor cells (CTCs) during surgery to test the hypothe
Autor:
Juergen Wolf, Sylvestre Le Moulec, Daniel Morgensztern, Benjamin Besse, Satwant Lally, Sreeni Yalamanchili, Afshin Dowlati, Bonnie S. Glisson, Charles M. Rudin, Neal Ready, Laurent Greillier, Christine L. Hann, Rafael Santana-Davila, Anna F. Farago, Ramaswamy Govindan, David P. Carbone
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(23)
Purpose: Although extensive-stage small-cell lung cancer (SCLC) is highly responsive to first-line therapy, virtually all patients develop resistance with short survival. Rovalpituzumab tesirine (Rova-T) is an antibody–drug conjugate targeting delt
Autor:
Huaqiang Zhou, Xue Wu, Yang W. Shao, Jiani C. Yin, Wenfeng Fang, Yuxiang Ma, Fufeng Wang, Li Zhang, Yunpeng Yang, Yan Huang, Hongyun Zhao, Hua Bao, Shaodong Hong, Ao Wang
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(16)
Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer management. However, molecular determinants of response to ICIs remain incompletely understood. Experimental Design: We performed genomic profiling of 78 patients with non–small
Autor:
Jesse M. Zaretsky, Jacklin Gukasyan, John Madrigal, James M. Carroll, David Elashoff, Steven M. Dubinett, Jonathan W. Goldman, Daniel K. Wells, I. Peter Shintaku, Edward B. Garon, Antoni Ribas, Hira Rizvi, Benjamin P Jones, Dennis J. Slamon, Siwen Hu-Lieskovan, Aaron Lisberg, Matthew D. Hellmann, Tristan Grogan, Amy L. Cummings
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(16)
Purpose: Several biomarkers have been individually associated with response to PD-1 blockade, including PD-L1 and tumor mutational burden (TMB) in non–small cell lung cancer (NSCLC), and CD8 cells in melanoma. We sought to examine the relationship
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Autor:
Arantxa Uruñuela, Xuejing Aimee Wang, Alexander Drilon, Charles S. Fuchs, Sameera R. Wijayawardana, Ghassan K. Abou-Alfa, Brian A. Moser, Martin H. Voss, Johanna C. Bendell, T.K. Choueiri, Andrew X. Zhu, Volker Wacheck, Todd M. Bauer, James J. Harding
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(17)
Purpose: Inhibition of the VEGFR-2 blocks angiogenesis and attenuates tumor growth, but cancers may evade this effect through activation of the hepatocyte growth factor receptor MET. Here we report results of the phase Ib/II study of ramucirumab, a m
Autor:
Valérie Gounant, Radj Gervais, Virginie Westeel, Denis Moro-Sibilot, Julien Mazieres, Arnaud Scherpereel, Emilie Charton, Franck Morin, Olivier Molinier, C. Locher, Hervé Lena, H. Janicot, Frédéric Rivière, Clarisse Audigier-Valette, Jacques Margery, Guillaume Eberst, Gérard Zalcman, Isabelle Monnet, Laurent Greillier, Amélie Anota
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(19)
Purpose: The IFCT-GFPC-0701 MAPS phase III trial highlighted significant improvement in overall survival from adding bevacizumab to the standard first-line chemotherapy regimen [cisplatin plus pemetrexed (PC)] in advanced malignant pleural mesothelio